AccessibilityHelpAbout Us
MDxHealth logo

MDxHealth(NASDAQ) MDXH

Market Cap$60.11MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2009)-99%
5 Year-96%
1 Year-84%
1 Month-17%
$0.60
-4.76%
-0.03Today
MDxHealth last closing stock price
MetricPriceDate
Last closeUSD 0.632026-09-18
MDxHealth stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-10.59%USD 0.702026-09-11
1 month-17.01%USD 0.762026-08-19
3 month+16.02%USD 0.542026-06-18
Year to date-82.35%USD 3.572025-12-31
1 year-83.85%USD 3.902025-09-18
3 year-82%USD 3.502023-07-14
5 year-95.74%USD 14.802021-09-08
Since inception-99.28%USD 87.502009-06-15

MDxHealth Financials at a Glance

Market Cap

$60.11MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$156.54M

Net Income (TTM)

-$55.71M

EPS (TTM)

-$0.73

P/E Ratio

-0.86

Dividend

$0.00

Beta (Volatility)

13299.37 (High)

Price

$0.60

Volume

347,714.36

Open

$0.63

Previous Close

$0.60

Daily Range

$0.60 - $0.65

52-Week Range

$0.40 - $5.33

Estimated Earnings Date

Aug 13, 2026

MDXH News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About MDxHealth

MDxHealth S.A. is a commercial-stage precision diagnostics firm specializing in urologic solutions globally. The company offers innovative genomic testing for prostate cancer, significantly enhancing diagnostic accuracy while reducing the need for invasive procedures.

Products and Services
  • SelectMDx: A non-invasive urine test for prostate cancer detection
  • ConfirmMDx: An epigenetic diagnostic tool for confirming prostate cancer
  • Comprehensive support services for healthcare professionals and patients
Growth Outlook
  • Revenue of $27.2 million in Q2 2026, showing strong market demand
  • Gross profit margin improved to 65.7% in Q2 2026
  • Expansion into new European markets expected to drive future growth
Financial Highlights
  • Net income of -$11.5 million in Q2 2026, reflecting ongoing investment in R&D
  • Cash and cash equivalents of $19.2 million as of June 30, 2026
  • Operating expenses totaled $22.9 million in Q2 2026, indicating strategic growth initiatives
MDxHealth S.A. operates in the Medical - Diagnostics & Research industry, focusing on precision diagnostics for prostate cancer. The company has established a significant presence in the United States and various European countries, including the Netherlands, Belgium, and Spain. Its innovative products, SelectMDx and ConfirmMDx, are designed to improve the accuracy of prostate cancer diagnosis, thereby reducing the need for invasive procedures. The growth outlook for MDxHealth appears promising, with a notable revenue increase in the most recent quarter. The company is also focusing on expanding its market reach, which could further enhance its revenue streams. Financially, while the company reported a net loss, the gross profit margin indicates effective cost management and potential for future profitability as the market for precision diagnostics continues to grow. Investors may find MDxHealth S.A. an intriguing opportunity, given its innovative product offerings and strategic growth initiatives in a rapidly evolving healthcare landscape.
AI Generated • Sep 19, 2026

Industry

Biotechnology

Sector

Health Care

Employees

364

CEO

Michael K. McGarrity

Website

www.mdxhealth.com

Headquarters

Herstal, WA 4040, BE

MDXH Financials

Key Financial Metrics (TTM)

Gross Margin

57.64%

Operating Margin

-20.36%

Net Income Margin

-37.02%

Return on Equity

142.63%

Return on Capital

-18.55%

Return on Assets

-22.94%

Earnings Yield

-1.16%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$60.11MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

95.42M

Volume

347.71K

Avg. Volume

5.93M

Financials (TTM)

Gross Profit

$94.56M

Operating Income

-$29.28M

EBITDA

-$13.14M

Operating Cash Flow

-$15.80M

Capital Expenditure

-$859.00K

Free Cash Flow

-$16.66M

Cash & ST Invst.

$19.21M

Total Debt

$105.85M

MDxHealth Performance Analysis

MDxHealth annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 37,054,00066.6%
20232023-12-31USD 70,193,00089.4%
20242024-12-31USD 90,049,00028.3%
20252025-12-31USD 107,875,00019.8%
MDxHealth sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-3114.4%
Q22025-06-30-44.6%
Q42025-12-31105.5%
Q22026-06-30-50.2%
MDxHealth annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2.7816.7%
20232023-12-31USD -1.66-40.1%
20242024-12-31USD -1.16-30.4%
20252025-12-31USD -0.67-42.1%
MDxHealth sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-3147.9%
Q22025-06-3021.1%
Q42025-12-31-23.3%
Q22026-06-3040.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$27.21M

-35.2%

Gross Profit

$17.89M

-29.4%

Gross Margin

65.75%

N/A

Market Cap

$60.11MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$165.15K

N/A

Employees

364

N/A

Net Income

-$11.53M

+42.5%

EBITDA

-$1.01M

+88.8%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$19.21M

-10.0%

Total Debt

$105.85M

+86.8%

Accounts Receivable

$14.93M

+10.9%

Inventory

$6.43M

+71.4%

Long Term Debt

$104.04M

+91.2%

Short Term Debt

$1.80M

-20.0%

Return on Assets

-22.94%

N/A

Return on Invested Capital

-17.60%

N/A

Free Cash Flow

-$5.89M

+49.0%

Operating Cash Flow

-$5.85M

+40.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SNWVSANUWAVE Health Inc.
$4.44-2.42%
QTRXQuanterix Corporation
$3.04-0.98%
IMRXImmuneering Corporation
$4.44-0.89%
XGNExagen Inc.
$8.62+2.50%

Trending Stocks

Symbol / CompanyPricePrice Chg
WBDWarner Bros. Discovery
$30.80+10.79%
GRMLGreenland Mines
$9.42+230.53%
INTCIntel
$121.78+12.14%
NVDANvidia
$227.38+2.30%

Questions About MDXH

What is the current price of MDxHealth?

MDxHealth is trading at $0.60 per share.

What is the 52-week range for MDxHealth?

Over the past 52 weeks, MDxHealth has traded between $0.40 and $5.33.

How much debt does MDxHealth have?

As of the most recent reporting period, MDxHealth reported total debt of $105.85M.

How much cash does MDxHealth have on hand?

MDxHealth reported $19.21M in cash and cash equivalents in its most recent financial results.

What is MDxHealth’s dividend yield?

MDxHealth does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services